Phase III trial of zoliflodacin shows it as effective as current treatments for uncomplicated gonorrhea, highlighting its potential in combating rising antibiotic resistance.
Neisseria gonorrhoeae diplococci bacteria responsible for the sexually transmitted infection gonorrhea.
(Adobe Stock 139761858 by fotovapl)
Gonorrhea is an ancient disease and is the second most bacterial common sexually transmitted infection. In 2020, an estimated 82.4 million new infections among adults aged 15 to 49 globally, and pharmaceutical companies continue to search for new and better treatments for the disease. Recently, the Phase III zoliflodacin data was presented at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global held in Barcelona, Spain, from April 27 to 30, 2024.
In an exclusive interview, Infection Control Today® (ICT®) learned more about the study’s data from Matt Ronsheim, PhD, president of Innoviva Specialty Therapeutics.
ICT: Would you provide an overview of the Phase 3 trial results for oral zoliflodacin in treating uncomplicated gonorrhea, including the key findings presented at ESCMID Global 2024?
Matt Ronsheim, PhD: The Phase III study data presented at ESCMID Global 2024 by Alison Luckey, MD, GARDP, found that a single oral dose of zoliflodacin is noninferior to a combination of ceftriaxone (administered intramuscularly) and azithromycin (administered orally) for the treatment of uncomplicated urogenital gonorrhea. the trial demonstrated that “zoliflodacin was well tolerated with a favorable safety profile compared to ceftriaxone plus azithromycin.
Key takeaways from the presentation:
Background Detail:
Innoviva Specialty Therapeutics and our development partner GARDP, sponsored and conducted a global phase 3 pivotal trial of a single oral dose of zoliflodacin, an investigational, first-in-class antibiotic being developed for the treatment of uncomplicated gonorrhea infection. The trial compared zoliflodacin to a globally recommended regimen of 500mg ceftriaxone administered intramuscularly plus 1g azithromycin administered orally).
ICT: How does the microbiological cure rate achieved by oral zoliflodacin compare to the current global standard of care for gonorrhea treatment, and what implications does this have for future treatment strategies?
MR: The microbiological cure rates observed in the zoliflodacin arm and the ceftriaxone-azithromycin arm (micro-ITT population) were 90.9% (460/506) and 96.2% (220/238), respectively, representing a difference of 5.31% (95% CI: 1.38 to 8.65).
If approved, zoliflodacin will provide a new mechanism of action with no evidence of cross-resistance with other antibiotics. it has shown activity against multidrug-resistant strains, including those resistant to antibiotics typically used to treat gonorrhea, such as ceftriaxone, azithromycin, cefixime, penicillin, ciprofloxacin, and tetracycline. Additionally, zoliflodacin is delivered in a single oral sachet dose suspended in water.
While these cure rates are comparable, resistance to ceftriaxone, the current standard of care, consisting of the combination of ceftriaxone and azithromycin, is on the rise and likely to continue in the near future. New safe and effective agents such as zoliflodacin will be critical to address the medical need.
ICT: Could you elaborate on the significance of the collaborative effort between Innoviva Specialty Therapeutics and GARDP in developing zoliflodacin, particularly in addressing the challenges of antimicrobial resistance?
MR: This is the first collaborative study between industry (IST) and a non-profit organization (GARDP) to address infections associated with World Health Organization high-priority pathogen and CDC urgent threat.
The positive phase III findings offer hope for patients with gonorrhea, particularly in the face of rising antibiotic resistance to current regimens. If approved, zoliflodacin could become the first new antibiotic used solely for treating gonorrhea in decades. It's important to note that the bacterium Neisseria gonorrhoeae has gradually developed resistance to many classes of antibiotics used to treat these infections. As a result, ceftriaxone, given as a single intramuscular injection, has become the last available recommended treatment for gonorrhea globally.
Previous in vitro studies have shown that zoliflodacin is active against multidrug-resistant strains of Neisseria gonorrhoeae, including those resistant to ceftriaxone and azithromycin, with no cross-resistance with other antibiotics.
The World Health Organization estimates that more than 82 million new gonorrhea infections are occurring globally each year. Gonorrhea is the second most common bacterial sexually transmitted infection, affecting both men and women in a manner that can lead to serious and permanent health consequences.
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.